Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
Author:
Funder
Investigator Initiated Reaserch Grant from Pzizer
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/8/1748/25505064/mdy214.pdf
Reference14 articles.
1. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer;Miller;Cancer Discov,2011
2. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer;Thangavel;Endocr Relat Cancer,2011
3. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer;Wardell;Clin Cancer Res,2015
4. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro;Finn;Breast Cancer Res,2009
5. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016
Cited by 70 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment;Nature Reviews Clinical Oncology;2023-12-11
2. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial);Breast Cancer Research and Treatment;2023-03-31
3. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials;Endokrynologia Polska;2023-02-27
4. Circulating Tumor Cells in Breast Cancer;Interdisciplinary Cancer Research;2023
5. CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis;Therapeutic potential of Cell Cycle Kinases in Breast Cancer;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3